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Abstract 
Most patients with chronic disease are prescribed multiple medications, which are recorded in their 
personal health records. This is rich information for clinical public health researchers but also a challenge 
to analyse. This paper describes the method that was undertaken within the Public Health Research Data 
Management System (PHReDMS) to map medication data retrieved from individual patient health 
records for population health researcher’s use. The PHReDMS manages clinical, health service, 
community and survey research data within a secure web environment that allows for data sharing 
amongst researchers. The PHReDMS is currently used by researchers to answer a broad range of 
questions, including monitoring of prescription patterns in different population groups and geographic 
areas with high incidence/prevalence of chronic renal, cardiovascular, metabolic and mental health 
issues. In this paper, we present the general notion of abstraction network, a higher level network that 
sits above a terminology and offers compact and more easily understandable view of its content. We 
demonstrate the utilisation of abstraction network methodology to examine medication data from 
electronic medical records to allow a compact and more easily understandable view of its content. 
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Introduction 
Population health scientists aim to understand disease patterns and develop approaches for disease 
prevention, detection, and diagnosis at an early stage to reduce the burden of disease [1]. Within the 
last decade there has been a rapid increase in the availability of health care data and never before 
have population scientists had the capacity to collect, share, and analyse data as they have today. 
Population health researchers often collect data from patients directly or from their health service 
records. Personal health records (PHRs) of patients contain a wealth of information, but can be 
challenging to analyse [2]. There is a variety of paper and electronic medical records (EMRs) in 
use, despite ongoing attempts to standardise data collection and a variety of clinical coding systems 
implemented by EMR vendors [3]. Terminologies and terminological systems play an important 
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role in many medical information processing environments, giving rise to the “big knowledge” 
challenge, when terminological content comprises of tens of thousands to millions of concepts 
arranged in a non-relational manner [4]. The science of bioinformatics can provide essential tools 
and a framework for population scientists to manage this potentially overwhelming amount of data 
[1]. 
The challenge for Health Information Technology is to design systems that are powerful enough not 
only to handle the volume and complexity of medical data, but also to support both patients and 
professionals, resulting in improved health care, reduced costs and health outcomes for patients [2]. 
Data standardization and harmonization can address some of the obstacles to data sharing and 
pooling [3] [5] [6] [7]. Data harmonization is used when data standardization is not possible to 
achieve interoperability across systems. This work is laborious and entails a trans- disciplinary 
approach wherein informaticists, measurement and topical experts, biostatisticians, and ethicists 
combine their knowledge to ensure the integrity and security of harmonized data [5] [6]. One 
method applied to harmonise terminology is the abstraction network. 
An abstraction network overlays a terminology’s underlying network structure at a higher level of 
abstraction. In particular, it provides a more compact view of the terminology’s content, avoiding 
the display of minutiae [4]. The notion of an abstraction network is presented as a means of 
facilitating the usability, comprehensibility, visualization, and quality assurance of terminologies 
[8]. One very important feature of an abstraction network is that it is typically multiple orders of 
magnitude smaller in size than its underlying terminology. This compact structure makes 
abstraction networks much more manageable from visualization and comprehension perspectives 
[9]. The reduction in size of an abstraction network is obtained by structurally dividing a large 
terminology into smaller parts, each of which is represented by one constituent entity (node) of the 
abstraction network [4]. 
There are two main ways to define the set of nodes of an abstraction network, intrinsic and 
extrinsic. Intrinsic abstraction networks derive them from the concepts and relationships of the 
underlying terminology itself. That is, some terminology concepts are of a general nature and can 
be used to properly categorize other elements [4]. Another alternative for choosing nodes is by a 
domain expert gleaning broad categories, befitting the terminology’s subject matter, from external 
sources [4]. For example, the categories might be taken from the general body of literature in a 
subject area or from a standard reference work. An abstraction network derived in this way from 
sources external to the terminology itself is called extrinsic. For example, for a terminology in the 
medical field, broad categories could be disease, laboratory test, and procedure. Extrinsic networks 
do put a burden on the designer in terms of determining the level of refinement [4]. 
The aim of this study was to map medication data retrieved from individual patient health records 
for population health researcher’s use through the use of an abstraction network to create a compact 
and more easily understandable view for public health research. 
Methods 
The modelling of medication data within PHReDMS was based on the Monthly Index of Medical 
Specialties (MIMS) [10]. In Australia MIMS is commonly used to define independent medicine 
information used by Australian healthcare professionals. Medications within MIMS are classified 
by: 
- The body system for which the medicine is used, e.g. cardiovascular system 
- Medication class, e.g. beta-adrenergic blockers 
- Medication subcategory, e.g. rapid acting (under insulins) 
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- Route, e.g. inhaled, topical, anorectal 
-Medication brand & generic name 
Medications within patient records are often recorded with both Brand and Generic names being 
used interchangeably during the prescribing process. Whilst a category of medication may have 
utility across multiple medical conditions, MIMS medication subcategories are made up of drugs 
that are similar in terms of both function and formulation. The formulation of any given medication, 
in terms of its constituent compounds and their function, remains similar regardless of 
pharmaceutical producer, brand or generic naming. For example, beta blockers are a subcategory of 
anti-hypertensive drugs. Atenolol (brand names include Noten & Tenormin) and propranolol 
(commonly branded as Apo-Propranolol) are both beta blockers. The active ingredient in atenolol is 
always a benzacetamide compound named atenolol, and in propranolol it is propranolol 
hydrochloride. Both compounds/ active ingredients exert a therapeutic effect by blocking beta 
adrenergic receptors. For research purposes, we might want to analyse data at the level of beta 
receptor blockers, or at anti-hypertensives, or even at a higher level of all drugs that exert an action 
upon the cardiovascular system. 
A working group comprising of a database administrator, a three person database development 
team, two researchers and a principal investigator met on an as needed basis to develop the 
medications mapping model. The researchers were qualified general medical practioners, who have 
a number of years of experience with patient medical record information. An electronic extract of 
medications from a clinical information system was compared to the MIMS database by the 
researchers. After primary classification of brand and generic medications by the researchers, the 
working group utilised an iterative process over multiple meetings to clarify the mapping. 
Medications within the PHReDMS were mapped based on active ingredients/constituent 
compounds (See Table 1 for an example). By basing categorisation on the common constituent 
compounds (often listed in the generic medication name) instead of nomenclature (brand or generic 
medication names), the working group were able to map medication into subcategories and 
categories to enable analysis on multiple levels from a single data collection, as well as aid 
categorisation of data from varied sources. 
Medications within the PHReDMS are mapped based on active ingredients/constituent compounds 
(Table 1). The MIMS database was used to link generic and brand names to active ingredients, with 
generic names often mirroring the active ingredient present. PHReDMS does not store the name of 
branded drugs, it only stores the ingredients. A custom built sql script extracting as many 
ingredients as are listed against the branded drug in Communicare. This was usually no more than 
three active ingredients. The PHReDMS attaches an active ingredient to any number of 
subcategories. Subcategory descriptors relate either to function or route of administration. 
Categories can be constituted of multiple subcategories and multiple categories can be used to treat 
a particular health condition. An exception column exists to detail any medications that deviate in 
function from the rest of their class. 
Medication categories recorded in PHReDMS were examined, with medications focused to the 
major medication classes and of interest to the research group. However this model can be scaled to 
include more categories of medication as required. Each medication category contains an Other 
subcategory, to classify any new medications that do not fall into pre-existing subcategories. There 
is also an overall Other category, to classify any medications extracted that do not fall into the 
limited categories as defined in PHReDMS. New medications which fall into existing subcategories 
or categories can be added by the researcher forwarding their details to the database administrator. 
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Table 1: Medication Mapping Model in PHReDMS 
Brand name Generic name/ 
active 
compound 
Function Medication 
subcategory 
Medication 
category 
Apo carvedilol carvedilol Non 
selective 
beta blocker 
Beta blocker Anti-hypertensive 
medication 
Dilatrend carvedilol Non 
selective 
beta blocker 
Beta blocker Anti-hypertensive 
medication 
Coveram amlodipine  Calcium channel 
blocker 
Anti-hypertensive 
medication 
 Perindopril 
arginine 
ACE inhibitor 
Results 
Initially there were 7416 medications extracted from the Communicare from which were derived a 
list of 601 compounds. These compounds were then mapped into 63 sub-categories and 19 
categories. Nutritional supplements have been collapsed to just their generic compounds as they are 
primary data for the researchers using the PHReDMS (Table 2). 
Table 2: Medication Categories Recorded in The Public Health Research Data Management 
System. 
Category Subcategory 
Full name Full name Abbreviation 
Insulins   
 Short acting insulins Short 
 Long acting insulins Long 
 Intermediate acting insulins Intermediate 
 Rapid acting insulins Rapid 
 Mixed insulins Mixed 
Oral hypoglycaemic agents   
 Biguanides  
 Sulphonylureas  
 Thiazolidinediones  
 Alpha-glucosidase inhibitors  
 Meglitinides  
 Dipeptidyl peptidase-4 inhibitors DPPIs 
Antihypertensives   
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 Beta blockers B-blockers 
 Angiotensin Converting Enzyme inhibitors ACE 
Inhibitors 
 Calcium channel blockers Ca channel 
blockers 
 Centrally acting antihypertensive agents Centrally 
acting 
 Sympatholytics  
 Other Antihypertensives  
 Angiotensin 2 receptor antagonists A2 antagonists 
Vasodilators   
 Nitrates  
 Other Vasodilators  
Diuretics   
 Thiazides  
 Potassium sparing diuretics K+ 
 Other diuretics  
 Loop diuretics Loop 
Antiarrhythmics   
 Class I  
 Class IA  
 Class IB  
 Class IC  
 Class II  
 Class III  
 Class IV  
 Class V  
Antibiotics   
 Penicillins  
 Macrolides  
  Quinolones  
  Rheumatic Heart disease RHD 
  Other antibiotics  
Nutritional Supplements   
 Fatty acids  
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 Vitamins  
 Minerals  
 Other supplements  
 Folates & derivatives Folates 
Vaccines   
Urinary Acidifiers   
Urinary Alkalinisers   
   
Hypolipidaemics   
 Serum cholesterol reductors  
 3-hydroxy-3-methylglutaryl-coenzyme 
(HMG-CoA) reductase inhibitors 
HMG CoA 
inhibitors 
 Fibrates  
 Intestinal absorption inhibitors  
 Bile acid sequestrants  
 Other hypolipidaemics  
Anticoagulants   
 Anti Factor Xa  
 Antiplatelet aggregation  
 Antithrombotic  
 Thrombin Inhibitors  
 Coumarins  
 Superfiial thromboses  
 Other anticoagulants  
Antifungals   
Corticosteroids   
 Glucocorticoids  
 Mineralcorticoids  
 Other corticosteroids  
Alpha blockers   
Anti-asthmatics   
 Beta2 agonists  
 Anticholinergics  
 Inhaled corticosteroids  
 Other bronchodilators  
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Anaesthetics   
Other   
Discussion 
One way to confront the “big knowledge” challenge is to provide auxiliary support structures to aid 
in terminology use and maintenance [4]. Highly interactive partially-automated mapping tools that 
are directed by human input to automate parts of the mapping process, with specific expert input, 
are a promising alternative to fully automated methods [11]. In this study we were able to 
successfully use an abstraction network to map medication data from patient electronic medical 
records. This enables patient information to be easily utilised by population health researchers. 
Patient health information is largely stored in EMRs, which are used by most health care providers 
for the regular documentation of care provided. Administrators also use EMRs for purposes of 
reporting upon and monitoring activities in health facilities. Whilst some patient data is still stored 
in paper format, researchers are increasingly asking to access EMR data for the purposes of 
population level research, including the development of clinical decision support tools. The vast 
amounts and complexity of information within EMRs complicates information management for 
each of these groups and increases the risk of incorrect decisions being made due to the difficulties 
of sifting through so much information. Likewise with paper records, the amount, variability and 
complexity of information stored within them makes it difficult to collect and analyse this data in a 
reliable manner. Managing medications data is a particular challenge; as the burden of chronic 
disease increases in the population [12] so do issues related to polypharmacy and its management 
[13] [14] [15]. Clinicians and researchers need new tools to manage medication- related 
information. Although there can be an overwhelming number of medications and medicine classes 
prescribed per patient, pharmacology is relatively structured when it comes to classification of the 
active ingredients or constituents of medication. Additionally, various therapeutic guidelines are 
available that are already in use in practice to thoroughly document and categorise medication, 
ensuring relatively easy access to the expert opinions required to inform any medications mapping. 
For research purposes, data is sourced from various EMRs and paper patient files, which capture 
medications data related to MIMS in different formats. A research database like PHReDMS needs 
to be flexible enough to contain medications data; 
1. From various sources, which may or may not be inter-relatable 
2. Across various topics, which are externally set by researchers accessing the database 
3. That reflects changes over time 
Limitations 
The development of the abstraction network to manage medication records for individual patient’s 
for chronic disease management research has been extremely labour intensive. The abstraction 
network requires updating before new patient records are added to an individual research project to 
capture new medications that have been recently released into the population. 
Conclusion 
Mapping in the manner described above has enabled data to be categorised to allow researchers to 
query and analyse it at multiple levels (disease grouping, category, subcategory, and compound) 
relevant to their particular research question, without compromising the richness of individual level 
medications data. It allows all data collected by various researchers from various sources to be 
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aggregated into one database, thus providing a valuable source of population level data. The 
mapping process is geared towards population level chronic diseases medication data, and will need 
to be expanded for uses outside of this scope (e.g oncology) however the system is flexible enough 
to enable this as may be required in the future. 
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